Dynatronics Corporation Advances Business and Product Portfolio Optimization Plan
Dynatronics Corporation (NASDAQ:DYNT) has announced significant strategic changes aimed at enhancing financial performance and streamlining operations by eliminating approximately 1,600 low-margin products. This optimization plan focuses on leveraging Dynatronics' manufacturing capabilities, targeting higher margins, and consolidating support functions. The company anticipates a $1.2 million restructuring charge, with an expected $11 million reduction in annual sales for FY '22 but aims for improved gross margins and EBITDA. Challenges from severe weather and COVID-19 impact Q3 FY '21 sales, estimated at $11.4 million.
- Elimination of 1,600 low-margin SKUs is aimed at enhancing profitability.
- Focus on high-margin, differentiated products manufactured by Dynatronics will improve EBITDA.
- Streamlining operations may strengthen the balance sheet and support potential M&A.
- Expected $11 million reduction in annual net sales for FY '22 compared to FY '21.
- Q3 FY '21 sales projected at $11.4 million, down from $13.7 million in the previous year.
Strategic actions announced today eliminate low-margin, distributed products
EAGAN, MN / ACCESSWIRE / April 22, 2021 / Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, announces strategic actions taken to improve the company's overall financial performance consistent with previously announced plans to optimize the business.
"Today marks a significant step towards a scalable and sustainable revenue and growth model as well as higher margins for our business," said John Krier, President and CEO of Dynatronics Corporation. "By eliminating low-margin distributed products and associated support costs within our physical therapy and rehabilitation lines, we will focus exclusively and more effectively on leveraging our own manufacturing capabilities and brands to better serve our customers."
Summary of Optimization Changes Announced Today
Drive Sales Growth and Better Partner with Customers
- Eliminate approximately 1,600 SKUs of low-margin, third-party distributed products, which are unprofitable, low growth, and add complexity.
- Focus sales and marketing resources on products manufactured by Dynatronics.
- Streamline sales exclusively to dealers, thereby eliminating perceived competition with customers from historic direct sales efforts.
Expand Margins and Profitability
- Focus on higher margin, differentiated products manufactured by the company.
- Consolidate support functions to reflect this focus.
- Target significant accretion to EBITDA and profitability through this optimization.
- Strengthen balance sheet via sustainable cash flow from operations, which can support additional investment and/or M&A in target markets.
Mr. Krier continued, "Dynatronics is well-positioned for a return to organic revenue growth, and improvements in margins and cash flow in FY '22. We see opportunities for more rapid organic growth in existing and adjacent markets. We are committed to ongoing business model enhancements, including through potential M&A transactions."
The company expects to record approximately
Q3 and Q4 Fiscal Year 2021 Outlook
Q3 FY '21 sales are expected to be approximately
Fiscal Full-Year 2022 Outlook
Most of these optimization initiatives are projected to be completed before the start of our FY '22 on July 1, 2021. Management estimates that the elimination of low-margin, distributed products will result in an approximately
In addition to the
About Dynatronics Corporation
Dynatronics Corporation is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Dynatron Solaris®, Hausmann™, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Safe Harbor Notification
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Those statements include references to the company's expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our statements regarding expected improvement in overall performance, anticipated recovery in revenues, improvements in cash flows and operating margins, rapid organic growth in existing and adjacent markets, expected costs and expenditures associated with the restructuring, outlook for fiscal year 2021 third and fourth quarters, estimated reductions in revenues year-over-year in fiscal year 2022 operating results, expectations that the company will deliver higher annual gross margins, operating income and EBITDA in fiscal year 2022 compared to fiscal year 2021, and expectations regarding reduction in occupied space in fiscal year 2022, and uncertainties involving the impact of the COVID-19 pandemic on the company's results of operations and financial condition, These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. This financial information is preliminary, has not been audited and is subject to change upon completion of the company's closing procedures. Additional information and disclosure would be required for a more complete understanding of the company's financial position and results of operations as of the fiscal quarter ended March 31, 2021. Moreover, even if the company's actual results are consistent with these preliminary estimates, this information may not be indicative of results or developments that may be expected in subsequent periods. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the company's annual, quarterly and other reports filed with the Securities and Exchange Commission. Dynatronics does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
EBITDA as used in this press release is a non-GAAP measure as defined under the rules of the Securities and Exchange Commission. We define EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization.
Investor Contacts:
Dynatronics Corporation
Investor Relations
Skyler Black
(801) 676-7201
ir@dynatronics.com
Darrow Associates
Peter Seltzberg, Managing Director
(516) 419-9915
pseltzberg@darrowir.com
For additional information, please visit: www.dynatronics.com
Connect with Dynatronics on LinkedIn
SOURCE: Dynatronics Corporation
View source version on accesswire.com:
https://www.accesswire.com/641562/Dynatronics-Corporation-Advances-Business-and-Product-Portfolio-Optimization-Plan
FAQ
What strategic changes did Dynatronics announce on April 22, 2021?
How will the changes affect Dynatronics' sales in FY '22?
What are the anticipated restructuring charges for Dynatronics?
What is the projected sales figure for Dynatronics in Q3 FY '21?